ASH: Sanofi uncorks late-stage data for RNAi drug fitusiran in hemophilia, with all eyes on safety profile

Kyle Blankenship

Sanofi’s fitusiran has had a rough road in hemophilia, weathering clinical holds and program halts tied to its lingering safety woes. Now, the drug is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ASH: Sanofi uncorks late-stage data for RNAi drug fitusiran in hemophilia, with all eyes on safety profile

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

ASH: Sanofi un­corks late-stage da­ta for RNAi drug fi­tusir­an in he­mo­phil­ia, with all eyes on safe­ty pro­file

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ASH: Sanofi uncorks late-stage data for RNAi drug fitusiran in hemophilia, with all eyes on safety profile